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Abstract Resveratrol, a phytoalexin, reduced the viabil-
ity of MH7A cells, a human rheumatoid arthritis synovial
cell line. In the apoptosis assay, resveratrol increased
TUNEL-positive cells and stimulated H2A.X phosphory-
lation. Resveratrol disrupted mitochondrial membrane
potentials in MH7A cells and stimulated cytochrome c
release from the mitochondria to the cytosol. Resveratrol
activated caspase-3 and caspase-9 but not caspase-8 in
MH7A cells. Resveratrol upregulated the expression of the
NAD-dependent deacetylase sirtuin 1 mRNA and down-
regulated the expression of the Bcl-XL mRNA, and res-
veratrol-induced MH7A cell death, mitochondrial damage,
and caspase-3/-9 activation were prevented by sirtinol, an
inhibitor of sirtuin 1. The results of the present study show
that resveratrol induces MH7A cell apoptosis by activating
caspase-9 and the effector caspase-3 along mitochondrial
disruption as a result of reduced Bcl-XL expression,
allowing cytochrome c release from the mitochondria into
the cytosol, in a sirtuin 1-dependent manner. This suggests
that resveratrol could suppress hyperplasia of synovial
cells, a critical factor of rheumatoid arthritis.
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Introduction
Rheumatoid arthritis is a systemic autoimmune disease
characterized by chronic inﬂammation of multiple joints,
with disruption of joint cartilage. Lines of evidence have
pointed to inﬂammatory cytokines inducing hyperplasia of
synovial cells in joints as an etiology for rheumatoid
arthritis. Of cytokines, tumor necrosis factor-a (TNF-a) and
interleukin-1 (IL-1) have been highlighted, since high
concentrations of TNF-a and IL-1 are found with the
synovial ﬂuid and the plasma for patients with rheumatoid
arthritis [1, 2] and those cytokines produce matrix
metalloproteinases or activate osteoclasts, causing irre-
versible damage to soft tissues and bones [3]. TNF-a
inhibitors, anti-TNF antibodies, a soluble TNF receptor
fusion protein, and an IL-1 receptor antagonist have been
attempted for treatment of rheumatoid arthritis, but their
side effects such as serious infections and inducible
malignant tumors remain not to be resolved [4].
Resveratrol, a phytoalexin that is present in grape skin
and red wine, exerts a variety of actions to reduce super-
oxides, suppresses cartinogenesis and angiogenesis, pre-
vent diabetes mellitus, inhibit inﬂammation, or prolong life
span [5]. Furthermore, resveratrol decreases plaque for-
mation relevant to neurodegenerative diseases such as
Alzheimer disease and Huntington disease [6]. Of partic-
ular interest is that resveratrol is potent and speciﬁc
inhibitor of NF-jB activation induced by TNF-a or IL-1b,
and therefore, resveratrol might be available for therapy of
rheumatoid arthritis [7–9].
The present study aimed at understanding the mecha-
nism of resveratrol-induced apoptosis in MH7A cells, a
human rheumatoid arthritis synovial cell line. We show
here that resveratrol induces MH7A cell apoptosis by
activating caspase-9 and the effector caspase-3 in response
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This supports the possibility for resveratrol as a beneﬁcial
drug for the treatment of rheumatoid arthritis.
Materials and methods
Cell culture
MH7A cells were obtained from Riken cell bank (Ibaraki,
Japan). Cells were cultured in a culture medium; RPMI-
1,640 (Wako, Osaka, Japan) supplemented with 10% heat-
inactivated fetal bovine serum (FBS), penicillin (ﬁnal
concentration, 100 U/ml), and streptomycin (ﬁnal concen-
tration, 0.1 mg/ml), in a humidiﬁed atmosphere of 5% CO2
and 95% air at 37C.
Cell viability
Cell viability was evaluated by the method using 3-(4,5-
dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide
(MTT) as previously described [10].
Terminal deoxynucleotidyl transferase-mediated dUTP
nick end labeling (TUNEL) assay
MH7A cells were ﬁxed with 4% paraformaldehyde. After
removing inactivate endogenous peroxidase with methanol
containing 0.3% H2O2, a permeabilization buffer was
applied to cells and stood on ice for 5 min. Then, a
Labeling Reaction Mixture was added and incubated in a
humidiﬁed chamber at 37C for 60 min. Reactive cells
were stained with 3% methyl green and detected with a
light microscope.
H2A phosphorylation assay
MH7A cells were incubated in a chemiluminescence
detection assay kit (Upstate, Charlottesville, Virginia,
USA) and reacted with an anti-phospho-H2A.X (Ser139)
followed by an anti-mouse-HRP conjugate. Phosphoryla-
tion of H2A.X at Ser139 was stained with a chemilumi-
nescent HRP substrate LumiGLO, and signals were
detected with a microplate luminometer (ARVO mx/light,
Perkinelmer, Waltham, MA, USA).
Assay of mitochondrial membrane potentials
Mitochondrial membrane potentials were measured using a
DePsipher
TM kit as previously described [10]. Brieﬂy,
MH7A cells were untreated and treated with resveratrol
(100 lM) in the absence and presence of sirtinol (10 lM)
for 24 h. After washing with cold phosphate-buffered sal-
ine (PBS), cells were incubated in a DePsipher
TM solution
at 37C for 20 min. Then, cells were washed with 1 ml of a
reaction buffer containing a stabilizer solution. The ﬂuo-
rescent signals were observed with a laser scanning
microscopes (LSM 510, Carl Zeiss Co., Ltd, Germany)
equipped with an epiﬂuorescence device using a ﬂuores-
cein long-pass ﬁlter (ﬂuorescein and rhodamine) at an
absorbance of 590 nm for red aggregations and at an
absorbance of 530 nm for green aggregations.
Reverse transcription–polymerase chain reaction
(RT–PCR)
Total RNAs of MH7A cells before and after treatment with
resveratrol (100 lM) were puriﬁed by an acid/guanidine/
thiocyanate/chloroform extraction method using a Sepasol-
RNA I Super kit. After puriﬁcation, total RNAs were treated
with RNase-free DNase I (2 unit) at 37C for 30 min to
remove genomic DNAs, and 10 lg of RNAs were resus-
pended in water. Then, oligo dT primers, dNTP, 59
ﬁrst-strand buffer, and SuperScript III RNase H-reverse
transcriptase were added to the RNA solution and incubated
at 65C for 5 min followed by 60C for 1 min, 56C for
60 min, 58C for 60 min, 85C for 5 min to synthesize the
ﬁrst strand cDNA. Subsequently, 1 ll of the reaction solu-
tion was diluted with water and mixed with 10 9 PCR
reaction buffer, dNTPs, MgCl2, oligonucleotide, dimethyl-
sulfoxide [ﬁnal concentration, 5% (v/v)], and 1 unit of Taq
polymerase (Fermentas, St. Leon-Roth, Germany) (ﬁnal
volume, 20 ll). RT–PCR was carried out with a Takara
Thermal cycler Dice (Takara Co. Ltd., Shiga, Japan) pro-
grammed as follows: the ﬁrst one step, 94C for 2 min and
the ensuing 30 cycles, 94C for 1 s, 62C for 15 s, and 72C
Table 1 Primers used for RT–PCR
Gene name Sense primer Anti-sense primer Base pair
Bad CTGGGGCTGTGGAGATCCGGAGTCGCC TCACTGGGAGGGGGCGGAGCTTCCCC 320
Bak GAGCCCATTCCCACCATTCTACCT AGAGAGGAAGGGAGAGAACTGAGAGGAC 381
Bax GGGAGACACCTGAGCTGACC GGACTCCAGCCACAAAGATGG 404
Bcl-2 GAACTGGGGGAGGATTGTGGCC TCGACGTTTTGCCTGAAGACTGTTAA 486
Bcl-XL AGGGAGGCAGGCGACGAGTTT TGAAGAGTGAGCCCAGCAGAACCA 421
Srituin 1 ATTACTGAAAAACCTCCACGAACACAAAA GCCTACTAATCTGCTCCTTTGCCACTCT 379
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stained with ethidium bromide and visualized by 2% (w/v)
agarose electrophoresis.
Western blotting
After treatment with resveratrol (100 lM) for 6–24 h,
MH7A cells were harvested and centrifuged at 6009g for
10 min. After washing out with 1 ml of PBS, the pellet was
resuspended in 50 ll of a buffer A (20 mM Hepes, 10 mM
KCl, 1.5 mM MgCI2, 1 mM EDTA, 1 mM EGTA, 1 mM
dithiothreitol, 0.1 mM phenylmethylsulfonyl ﬂuoride,
250 mM sucrose, pH 7.5) and homogenized. The lysate
was centrifuged at 1,0009g for 10 min, and the superna-
tant was further centrifuged at 10,0009g for 1 h. The pellet
and supernatant were used as the mitochondria- and cyto-
sol-enriched fraction, respectively. Each fraction was loa-
ded on 12% sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS–PAGE) and transferred to polyvi-
nylidene diﬂuoride membranes. Blotting membranes were
blocked with TTBS (150 mM NaCl, 0.05% Tween20, and
20 mM Tris, pH 7.5) containing 5% BSA and subsequently
reacted with an anti-cytochrome c antibody (1:400)
(Chemicon, Billerica, MA, USA), followed by an HRP-
conjugated goat anti-mouse IgG antibody. Immunoreac-
tivity was detected with an ECL kit (GE Healthcare, NJ,
USA) and visualized using a chemiluminescence detection
system (FUJIFILM, Tokyo, Japan). Signal density was
measured with an Image Gauge software (FUJIFILM,
Tokyo, Japan).
Enzymatic assay of caspase activity
Caspase activation was measured using a caspase ﬂuoro-
metric assay kit (Ac-Asp-Glu-Val-Asp-MCA for a caspase-
3 substrate peptide; Ac-Ile-Glu-Thr-Asp-MCA for a
caspase-8 substrate peptide; and Ac-Leu-Glu-His-Asp-MCA
for a caspase-9 substrate peptide) as previously described
[10].
Results
Resveratrol induces apoptosis MH7A cells
IntheMTTassay,resveratrolreducedMH7Acellviabilityin
a concentration (1–200 lM)- and treatment time (24–72 h)-
dependent manner (Fig. 1a), suggesting that resveratrol
induces MH7A cell death. To examine whether it is due to
apoptotic cell death, we carried out TUNEL assay and H2A
phosphorylation assay. Resveratrol increased TUNEL-
positive cells in a concentration (100–200 lM)-dependent
Fig. 1 Resveratrol induces apoptosis in MH7A cells. a MH7A cells
were treated with resveratrol at concentrations as indicated for 24–72
h in serum-free culture medium, and cell viability was quantiﬁed with
an MTT assay. In the graph, each point represents the mean (±SEM)
percentage of basal levels (MTT intensities for cells untreated with
resveratrol) (n = 8). b Cells were treated with resveratrol at
concentrations as indicated for 24 h in serum-free culture medium,
and TUNEL-positive cells were counted. In the graph, each column
represents the mean (±SEM) percentage of basal levels (TUNEL-
positive cell numbers without resveratrol treatment) (n = 3–6).
P values, unpaired t-test. c Cells were treated with resveratrol at
concentrations as indicated for 24 h in FBS-free culture medium, and
H2A.X phosphorylation was quantiﬁed. In the graph, each column
represents the mean (±SEM) ratio against basal levels (H2A.X
phosphorylation without resveratrol treatment) (n = 4). P values,
unpaired t-test
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123manner (Fig. 1b), indicating that resveratrol induces MH7A
cell apoptosis. DNA damage or apoptosis is recognized to
stimulate phosphorylation of histone H2A.X. Resveratrol
(100 lM) signiﬁcantly enhanced H2A.X phosphorylation,
the extent reaching approximately 13 folds of control levels
(Fig. 1c). This provides further evidence for resveratrol-
induced MH7A cell apoptosis.
Resveratrol disrupts mitochondrial membrane
potentials in a sirtuin 1-dependent manner
Resveratrol is shown to regulate mitochondrial functions or
calories by interacting with NAD-dependent deacetylase
sirtuin 1 [11, 12]. Interestingly, resveratrol-induced MH7A
cell death was inhibited by sirtinol (10 lM), an inhibitor of
sirtuin 1 (Fig. 2), suggesting that resveratrol induces
MH7A cell death in a sirtuin 1-dependent manner. More-
over, the resveratrol effect was inhibited by trichostatin A
(30 nM), and inhibitor of histone deacetylase (HDAC)
(Fig. 2). This may account for the implication of sirtuin
1-regulated apoptosis-related gene transcription in the
resveratrol effect.
To see whether resveratrol-induced MH7A cell apoptosis
is mediated via the mitochondria, mitochondrial membrane
potentials were monitored. For untreated cells, orange-red
ﬂuorescentsignalsalonewerefound(Fig. 3a,b).Incontrast,
resveratrol (100 lM) accumulated green ﬂuorescent signals
withoutorange-redﬂuorescentsignal(Fig. 3c,d),indicating
that resveratrol disrupts mitochondrial membrane potentials
in MH7A cells. The resveratrol effect on mitochondrial
membrane potentials was abolished by sirtinol (10 lM)
(Fig. 3e, f). This implies that resveratrol disrupts mito-
chondrial membrane potentials in MH7A cells under the
controlofsirtuin1.Takentogether,theseresultsindicatethat
resveratrol induces MH7A cell apoptosis by damaging the
mitochondria in a sirtuin 1-dependent manner.
In the RT–PCR analysis, resveratrol (100 lM) increased
the expression of the sirtuin 1 mRNA in MH7A cells in a
treatment time (20–60 min)-dependent manner (Fig. 4a).
This points to sirtuin 1 as a signiﬁcant target in resveratrol-
induced MH7A cell death. Accumulating evidence has
shown that resveratrol upregulates or downregulates the
expression of the Bcl-2 family that includes Bcl-2 and Bcl-
XL, to prevent from mitochondrial damage, and Bad, Bax,
and Bak, to induce mitochondrial damage [13]. Resveratrol
(100 lM) downregulated the expression of the Bcl-XL
mRNA in MH7A cells from 1-h through 3-h treatment
Fig. 2 Resveratrol-induced MH7A cell death is inhibited by a sirtuin
1 inhibitor or an HDAC inhibitor. MH7A cells were treated with
resveratrol (100 lM) in the absence and presence of sirtinol (10 lM)
or tricostatin A (TSA) (30 nM) for 24 h in serum-free culture
medium, and cell viability was quantiﬁed with an MTT assay. In the
graph, each column represents the mean (±SEM) percentage of basal
levels (MTT intensities for cells untreated with any drug) (n = 4).
P values, unpaired t-test
Fig. 3 Resveratrol disrupts mitochondrial membrane potentials in a
SIRT1-dependent manner. MH7A cells were treated with resveratrol
(100 lM) in the absence and presence of sirtinol (10 lM) for 24 h in
serum-free culture medium, and mitochondrial membrane potentials
were monitored. a, c, e Orange-red ﬂuorescent images at an
absorbance of 590 nm. b, d, f Green ﬂuorescent images at an
absorbance of 530 nm. Note that similar results were obtained with 3
independent experiments
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123(Fig. 4c), while it had no effect on expression of mRNAs for
Bcl-2 (Fig. 4b), Bad (Fig. 4d), Bax (Fig. 4e), and Bak
(Fig. 4f). Collectively, resveratrol may disrupt mitochon-
drial membrane potentials by reducing Bcl-XL expression
through a pathway relevant to sirtuin 1-mediated
transcription.
Resveratrol activates caspase-3 and caspase-9 through
mitochondrial damage in a sirtuin 1-dependent manner
Mitochondrial damage allows release of apoptosis-related
factors including cytochrome c. In the Western blot
analysis using the mitochondrial and cytosolic component
from MH7A cells, resveratrol (100 lM) increased the
presence of cytosolic cytochrome c in parallel with a
treatment time (3–24 h)-dependent decrease in the pres-
ence of mitochondrial cytochrome c (Fig. 5). This explains
that resveratrol stimulates release of cytochrome c from the
mitochondria into the cytosol.
In the enzymatic assay of caspase activity, resveratrol
(100 lM) signiﬁcantly activated caspase-3 and caspase-9,
but no activation of caspase-8 was obtained (Fig. 6). Res-
veratrol-induced activation of caspase-3 and caspase-9 was
inhibited by sirtinol (10 lM) (Fig. 6). Consequently, the
Fig. 4 Resveratrol upregulates
the expression of the sirtuin 1
mRNA and downregulates the
expression of the Bcl-XL
mRNA. MH7A cells were
untreated (Control) and treated
with resveratrol (100 lM) for
20–60 min or 0.5–3 h in serum-
free culture medium, and then
RT–PCR was carried out. In the
graph, each point represents the
ratio against the intensity at
0 min/h regarding as 1. Note
that similar results were
obtained with 3 independent
experiments
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effector caspase-3 in association with mitochondrial dam-
age allowing cytochrome c release in a sirtuin-dependent
manner, to induce MH7A cell apoptosis.
Discussion
In the present study, resveratrol reduced the viability of
MH7A cells, a human rheumatoid arthritis synovial cell
line. Resveratrol increased TUNEL-positive cells and
stimulated H2A.X phosphorylation, which conﬁrms res-
veratrol-induced MH7A cell apoptosis. Resveratrol dis-
rupted mitochondrial membrane potentials in MH7A cells,
stimulated cytochrome c release from the mitochondria
into the cytosol, and activated caspase-3 and caspase-9. For
a mitochondria-mediated apoptotic pathway, damaged
mitochondria releases apoptosis-related proteins such as
cytochrome c, apoptosis-inducing factor (AIF), Smac/
DIABLO, Omi/HtrA2, and endonuclease G into the cyto-
sol, and released cytochrome c activates caspase-3 by
forming an apoptosome complex together with apoptosis
proteases activating factor-1 (Apaf-1) and caspase-9 [14].
Resveratrol, accordingly, appears to induce MH7A cell
apoptosis by activating caspase-9 and the effector caspase-
3 in concert with mitochondrial disruption allowing cyto-
chrome c release from the mitochondria into the cytosol.
Amazingly, resveratrol upregulated the expression of the
sirtuin 1 mRNA in MH7A cells, and resveratrol-induced
MH7A cell death, mitochondrial damage, and caspase-3/-9
activation were prevented by a sirtuin 1 inhibitor. This
conﬁrms that sirtuin 1 plays a critical role in resveratrol-
induced MH7A cell apoptosis. Sirtuin 1 may regulate
apoptosis-related gene transcription mediated by FOXO or
NF-jB[ 16, 17]. The Bcl-2 family keeps mitochondrial
integrity and controls release of mitochondrial proteins
such as cytochrome c from the mitochondria. In the present
study, resveratrol downregulated the expression of the Bcl-
XL mRNA in MH7A cells, although expression of mRNAs
for Bcl-2, Bax, Bad, and Bak was not affected. This, taken
together with the ﬁnding that resveratrol-induced MH7A
cell death was attenuated by an HDAC inhibitor, raises the
possibility that resveratrol perturbs mitochondrial mem-
brane potentials by downregulating Bcl-XL gene tran-
scription in a sirtuin 1-dependent manner, followed by
mitochondrial apoptotic events.
In the previous study, resveratrol-induced apoptosis in
ﬁbroblast-like synoviocytes derived from patients with
rheumatoid arthritis by activating caspase-8 as a primary
target, which cleaves Bid, causing mitochondrial damage
that triggers the activation of caspase-9 and the effector
caspase-3, without affecting the levels of Bax, Bcl-XL, and
Bcl-2 [15]. The resveratrol action there is completely dis-
tinct from the action found in the present study. For res-
veratrol-induced MH7A cell apoptosis, sirtuin 1, that
downregulates expression of the Bcl-XL mRNA, was a
primary target of resveratrol, and no activation of caspase-8
was obtained. This may represent an additional resveratrol
action on apoptosis in human rheumatoid arthritis synovial
cells. The reason for difference in the resveratrol actions
between ﬁbroblast-like synoviocytes and MH7A cells,
however, remains to be explored.
In summary, the results of the present study show that
resveratrol disrupts mitochondrial membrane potentials as
Fig. 5 Resveratrol stimulates cytochrome c release from the mito-
chondria. MH7A cells were treated with resveratrol (100 lM) for
3–6 h in serum-free culture medium, followed by fractionation into
the mitochondrial (M) and cytosolic component (C), and Western
blotting was carried out. In the graph, each point represents the ratio
against the immunoreactive intensity at 0 h for the mitochondrial
component regarding as 1. cyto c, cytochrome c. Note that similar
results were obtained with 3 independent experiments
Fig. 6 Resveratrol activates caspase-3 and caspase-9 in a SIRT1-
dependent manner. MH7A cells were treated with resveratrol
(100 lM) in the absence and presence of sirtinol (10 lM) for 24 h
in serum-free culture medium, and caspase activities were assayed. In
the graph, each column represents the mean (±SEM) ratio against
basal levels (caspase activities for cells untreated with any drug)
(n = 4–6). P values, unpaired t-test. NS not signiﬁcant
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123a result of decreased Bcl-XL expression, allowing cyto-
chrome c from the mitochondria into the cytosol, thereby
activating caspase-9 and the effector caspase-3, to induce
MH7A cell apoptosis in a sirtuin 1-dependent manner. This
suggests that resveratrol is capable of preventing hyper-
plasia of synovial cells. Resveratrol, therefore, could be
developed as a promising drug for the treatment of rheu-
matoid arthritis.
Acknowledgments We thank Dr. Miyazawa (Kissei Pharmaceuti-
cal Co., Ltd.) for his help in dealing with MH7A cells.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Eastgate JA, Symons JA, Wood NC, Grinlinton FM, di Giovine
FS, Duff GW (1988) Correlation of plasma interleukin-1 levels
with disease activity in rheumatoid arthritis. Lancet 2:706–709
2. Saxne T, Palladino MA Jr, Heinegard D, Talal N, Wollheim FA
(1998) Detection of tumor necrosis factor-a but not tumor
necrosis factor-b in rheumatoid arthritis synovial ﬂuid and serum.
Arthritis Rheum 31:1041–1044
3. Olsen NJ, Stein CB (2004) New drugs for rheumatoid arthritis.
N Engl J Med 350:2167–2179
4. den Broeder A, van de Putte L, Rau R, Schattenkirchner M, Van
Riel P, Sander O, Binder C, Fenner H, Bankmann Y, Velagapudi
R, Kempeni J, Kupper H (2002) A single dose, placebo controlled
study of the fully human anti-tumor necrosis factor- antibody
adalimumab (D2E7) in patients with rheumatoid arthritis.
J Rheumatol 9:2288–2298
5. Elliott PJ, Jirousek M (2008) Sirtuins: novel targets for metabolic
disease. Curr Opin Investig Drugs 9:371–378
6. Karuppagounder SS, Pinto JT, Xu H, Chen HL, Beal MF, Gibson
GE (2009) Dietary supplementation with resveratrol reduces
plaque pathology in a transgenic model of Alzheimer’s disease.
Neurochem Int 54:111–118
7. Elmali N, Baysal O, Harma A, Esenkaya I, Mizrak B (2007)
Effects of resveratrol in inﬂammatory arthritis. Inﬂammation
30:1–6
8. Molnar V, Garai J (2005) Plant-derived anti-inﬂammatory com-
pounds affect MIF tautomerase activity. Int Immunopharm
5:849–856
9. Penberthy WT (2007) Pharmacological targeting of IDO-medi-
ated tolerance for treating autoimmune disease. Curr Drug Metab
8:245–266
10. Yasuda Y, Saito M, Yamamura T, Yaguchi T, Nishizaki T (2009)
Extracellular adenosine induces apoptosis in Caco-2 human
colonic cancer cells by activating caspase-9/-3 via A2a adenosine
receptors. J Gastroenterol 44:56–65
11. Kaeberlein M, McDonagh T, Heltweg B, Hixon J, Westman EA,
Caldwell SD, Napper A, Curtis R, DiStefano PS, Fields S,
Bedalov A, Kennedy BK (2005) Substrate-speciﬁc activation of
sirtuins by resveratrol. J Biol Chem 280:17038–17045
12. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C,
Daussin F, Messadeq N, Milne J, Lambert P, Elliott P, Geny B,
Laakso M, Puigserver P, Auwerx J (2006) Resveratrol improves
mitochondrial function and protects against metabolic disease by
activating SIRT1 and PGC-1a. Cell 127:1109–1122
13. Shakibaei M, Harikumar KB, Aggarwal BB (2009) Resveratrol
addiction: to die or not to die. Mol Nutr Food Res 53:115–128
14. Wang X (2001) The expanding role of mitochondria in apoptosis.
Genes Dev 15:2922–2933
15. Byun HS, Song JK, Kim YR, Piao L, Won M, Park KA, Choi BL,
Lee H, Hong JH, Park J, Seok JH, Lee YJ, Kang SW, Hur GM
(2008) Caspase-8 has an essential role in resveratrol-induced
apoptosis of rheumatoid ﬁbroblast-like synoviocytes. Rheuma-
tology 47:301–308
16. Giannakou ME, Partridge L (2004) The interaction between
FOXO and SIRT1: tipping the balance towards survival. Trends
Cell Biol 14:408–412
17. Salminen A, Kaarniranta K (2009) Regulation of the aging pro-
cess by autophagy. Trends Mol Med 15:217–224
Rheumatol Int (2012) 32:151–157 157
123